BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the initial dossier 
The  company  Syntex  Pharmaceuticals  Ltd  submitted  an  application  to  all  EU  Member  States  for 
CellCept capsules and tablets through the Concertation procedure (No 82) on 31 October 1994. 
A List B status as in the Annex to Directive 87/22/EEC was agreed by the CPMP in its June meeting 
1994. 
In  application  to  Article  2  of  Directive  93/41/EEC,  on  22  December  1994,  the  company  Syntex 
Pharmaceuticals  Ltd  transferred  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products, 
into  the  new  centralised  procedure,  the  application  for  Marketing  Authorisation  for  CellCept  falling 
within  the  scope  of  Part  B,  indent  7  of  the  Annex  to  Council  Regulation  (EEC)  2309/93  of  
22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: Dr Jefferys  
Co-Rapporteur: Dr Lyons  
Licensing status at the time of submission 
The medicinal product was authorised on 3 May 1995 in the USA.  
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The  Rapporteur's  initial  Assessment  Report  was  circulated  to  all  Members  of  CPMP  on  10 
January 1995. The Co-Rapporteur's initial Assessment Report was circulated to all Members of 
CPMP on 5 December 1994.  
The CPMP consolidated list of comments was sent to the applicant on 3 May 1995. 
The company submitted the responses to the consolidated list of comments on 20 June 1995. 
The Rapporteur’s first “responses” Assessment Report was circulated to all CPMP Members on 
7 August 1995. 
The  Co-Rapporteur’s  first  “responses”  preclinical  and  clinical  Assessment  Report  was 
circulated to all CPMP Members on 1 August 1995 and the Co-Rapporteur’s first “responses” 
pharmaceutical responses Assessment Report on 4 August 1995. 
The  company  provided  a  revised  Summary  of  Product  Characteristics  (SPC)  and  Package 
Leaflet (PL) on 22 August and 6 September 1995. 
The company provided a revised SPC on 12 September 1995. 
The  CPMP  considered  on  12-13  September  1995  the  written  clarifications  given  by  the 
company  on  some  minor  outstanding  points  as  well  as  the  revised  Summary  of  Product 
Characteristics  and  Package  Leaflet.  The  CPMP  agreed  on  the  SPC  and  requested  a  new  PL, 
specifically a new wording of the “Undesirable Effects” section. 
The company provided a new PL on 5 October 1995 in all 11 languages. 
The  company  submitted  on  10  October  1995  their  letter  of  commitment  for  providing 
information on quality points. 
In the light of the overall data submitted and the scientific discussion within the Committee, the 
CPMP issued a positive opinion for granting a Marketing Authorisation for two different oral 
presentations  of  CellCept  on  17  October  1995.  The  CPMP  opinions  were  forwarded,  in  all 
official  languages  of  the  European  Union  to  the  European  Commission,  which  adopted  the 
corresponding Decisions on 14 February 1996. 
1/1 
EMEA 2004 
 
 
 
  
